Neurology Central

Aimovig® gains US FDA approval for the preventive treatment of migraine

Novartis (Basel, Switzerland) and Amgen (CA, USA) have announced that the US FDA has approved Aimovig® (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.